Therapeutic Areas Doctors & Pharmacists

Cardiology

Cardiovascular diseases remain the most common cause of death in Austria.¹ Hypertension is a common cardiovascular disease, often associated with other fatal heart diseases such as stroke or myocardial infarction. The cardiovascular preparations of A. Menarini Pharma GmbH cover the indication areas hypertension, heart failure as well as stable angina pectoris.

The third-generation beta-blocker Nomexor^® (nebivolol) offers a broad range of indications thanks to its dual mechanism of action (highest ß1-selectivity of all oral beta-blockers², as well as the unique NO release at the endothelium³). Nebivolol is also available in combination with hydrochlorothiazide under the name Nomexor^® plus HCT.

From the group of angiotensin receptor blockers, Mencord^® (olmesartan), as well as the combination preparations Mencord^® Plus (olmesartan + hydrochlorothiazide), Amelior^® (olmesartan + amlodipine) and Amelior^® plus HCT (olmesartan + amlodipine + hydrochlorothiazide) are available, but must be paid for privately by the patient.

 Since 2010, A. Menarini Pharma GmbH has been offering Ranexa^® (ranolazine) as an add-on therapy in adults for the symptomatic treatment of stable angina pectoris when patients are inadequately treated or do not tolerate first-line antianginal agents such as beta-blockers or calcium antagonists.⁴

AT-WEB-40-10-2021